Citizens Initiates Coverage#
Citizens has started coverage on TuHURA Biosciences Inc. (NASDAQ:HURA), giving it a Market Outperform rating. This means they believe the stock will perform better than the overall market. They have set a price target of $9.00, which is significantly higher than the current trading price of $2.35. This price reflects a substantial discount compared to the target and is also 56% lower than its 52-week high of $4.20.
Company Overview#
TuHURA Biosciences is a clinical-stage company focused on immuno-oncology, which involves using the body’s immune system to fight cancer. The company was formed through the acquisition of Morphogenesis and Kineta, and is led by industry veteran James Bianco. Citizens highlighted TuHURA's innovative approach, which includes targeting a new myeloid checkpoint and potentially developing a new class of antibody-drug conjugates (ADCs) with a Delta Opioid Receptor payload.
Financial Insights#
The price target of $9 was derived using a discounted cash flow model, a method that estimates the value of an investment based on its expected future cash flows. However, it's important to note that TuHURA is currently burning through cash quickly and experiences high price volatility, which are critical factors for investors to consider.
Recent Developments#
In recent news, TuHURA secured a $50 million credit facility from K&V Investment One LLC, its largest stockholder. This funding will support clinical development and operations, with a 12% annual interest rate and repayment due by April 21, 2031. Additionally, Rodman & Renshaw has also initiated coverage on TuHURA with a buy rating and a price target of $7.00.
The company has approved performance bonuses and salary increases for its top executives, including a bonus of $490,536 for CEO Dr. James Bianco. New leadership appointments include Amanda Garofalo as Senior Vice President of Clinical Operations and Dr. Craig L. Tendler as Chief Medical Officer.